对于COVID-19住院患者的他类药物治疗,炎症和结果:一个前性的多中心队列研究
Anis Ismail1, Husam R Shadid2, Yiyuan Huang3
1Division of Cardiology, Department of Internal Medicine, University of Texas Medical Branch, Galveston.
The American journal of medicine
|August 23, 2024
概括
以前在住院COVID-19患者中使用他类药物与更好的结果和减少炎症有关. 这包括较低的死亡几率,机械呼吸和置换疗法,suPAR水平起着关键作用.
科学领域:
- 心脏病学 心脏病学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 以降脂和抗炎性质而闻名的他类药物,关于其在COVID-19中的益处有相互矛盾的数据.
- 了解他类药物对COVID-19相关炎症的影响至关重要.
研究的目的:
- 研究先前使用他类药物与住院COVID-19患者的临床结果之间的关联.
- 探索他类药物使用,炎症生物标志物和COVID-19严重程度之间的关系.
主要方法:
- 从2020年2月到2022年10月的前性多中心队列研究 (国际COVID-19炎症研究)
- 系统评估炎症生物标志物和逻辑回归与逆治疗概率权重 (IPTW).
- 检查了医院死亡,机械呼吸和脏替代疗法的复合结果.
主要成果:
- 包括4464名患者;27.5%之前接受过他类药物治疗.
- 斯坦丁使用与较低的可溶性尿激酶等离子素激活体受体 (suPAR) 水平相关.
- 斯坦丁使用与复合结果的几率降低相关 (aOR 0.63),结果与IPTW一致 (aOR 0.92).
结论:
- 以前使用他类药物与住院COVID-19患者的改善结果有关.
- 根据suPAR水平显示的下部炎症与该人群的他类药物使用有关.
- suPAR部分调解了他类药物对COVID-19结果的有益影响.
关键词:
在 COVID-19 疫情中,在CRP中使用CRP.死亡死亡死亡死亡死亡死亡死亡死亡透析是通过透析进行的.在IL-6的研究中,IL-6被认为是IL-6的基因.炎症 炎症是一种炎症.在 LDH 和 LDH 之间.在MYD8888中,我们可以使用MYD88机械通风机械通风机械通风机脏替代疗法是指脏替代疗法.这就是SARS-CoV-2病毒.史塔丁类药物是一种这就是SuPAR.更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.4K
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.6K
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
601
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
601
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
464
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
464
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162
01:28Pneumonia IV: Management
312
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
312
01:29Inflammatory Bowel Disease IV: Pharmacological Management
123
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
123